Ben Hargreaves finds that patient organisations are providing an increasingly essential role as a linker between patients and the rest of the life sciences industry.
In the intricate landscape of pharmaceutical advertising, treading the fine line between compliance and legal language regulations is comparable to a delicate tightrope walk.
Armed with new phase 3 data, Bayer has started to prepare for filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a
The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin